Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | RGS12 | O14924 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL845968 | 1.00 | SLC7A5 (0.49) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL188321 | 0.88 | SLC7A5 (0.57) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL188320 | 0.88 | SLC7A5 (0.57) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL2129884 | 0.88 | SLC7A5 (0.57) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL1356942 | 0.88 | SLC7A5 (0.57) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL1356944 | 0.88 | SLC7A5 (0.57) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL31688674 | 0.82 | MME (0.56) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL10064656 | 0.81 | SLC7A5 (0.56) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL31524255 | 0.81 | SLC7A5 (0.56) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL29009787 | 0.81 | PPARG (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4591934-A2 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BioMarin Pharmaceutical Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-4523749-A2 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BioMarin Pharmaceutical Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-12214015-B2 | Use of c-type natriuretic peptide variants to treat osteoarthritis | BIOMARIN PHARMACEUTICAL INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4029512-A1 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BioMarin Pharmaceutical Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-4019038-A2 | USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITIS | BioMarin Pharmaceutical Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220160836-A1 | USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITIS | BIOMARIN PHARMACEUTICAL INC. | 2022-05-26 | — | — | US | disclosed |
| US-11202819-B2 | Use of C-type natriuretic peptide variants to treat osteoarthritis | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3175863-B1 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BIOMARIN PHARM INC (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3386531-B1 | USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITIS | BIOMARIN PHARM INC (US) | 2021-10-13 | — | — | EP | disclosed |
| US-RE48267-E1 | Variants of C-type natriuretic peptide | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-8377884-B2 | Variants of C-type natriuretic peptides | BIOMARIN PHARMACEUTICAL INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120316114-A1 | Variants of C-type Natriuretic Peptide | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-8198242-B2 | Variants of C-type natriuretic peptide | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-06-12 | — | — | US | disclosed |
| CN-102481330-A | C-type natriuretic peptide variants | BIOMARIN PHARM INC | 2012-05-30 | — | — | CN | disclosed |
| EP-2432489-A2 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BioMarin Pharmaceutical Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20100331256-A1 | Variants of C-Type Natriuretic Peptides | BIOMARIN PHARMACEUTICAL INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2010135541-A2 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BIOMARIN PHARMACEUTICAL INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100297021-A1 | Variants of C-Type Natriuretic Peptide | BIOMARIN PHARMACEUTICAL INC. (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2217620-A2 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BioMarin Pharmaceutical Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009067639-A2 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BIOMARIN PHARMACEUTICAL INC. (US) | 2009-05-28 | — | — | WO | disclosed |